A detailed history of American International Group, Inc. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 20,095 shares of KYMR stock, worth $607,270. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,095
Previous 18,886 6.4%
Holding current value
$607,270
Previous $480,000 68.13%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$22.9 - $43.57 $27,686 - $52,676
1,209 Added 6.4%
20,095 $807,000
Q4 2023

Feb 13, 2024

SELL
$10.97 - $26.84 $833 - $2,039
-76 Reduced 0.4%
18,886 $480,000
Q3 2023

Nov 13, 2023

BUY
$13.9 - $23.88 $9,368 - $16,095
674 Added 3.69%
18,962 $263,000
Q2 2023

Aug 04, 2023

BUY
$22.4 - $34.92 $873 - $1,361
39 Added 0.21%
18,288 $420,000
Q1 2023

May 12, 2023

BUY
$24.84 - $38.75 $9,016 - $14,066
363 Added 2.03%
18,249 $540,000
Q4 2022

Feb 10, 2023

SELL
$19.57 - $30.92 $1,272 - $2,009
-65 Reduced 0.36%
17,886 $446,000
Q3 2022

Nov 14, 2022

BUY
$20.91 - $34.27 $5,290 - $8,670
253 Added 1.43%
17,951 $391,000
Q2 2022

Aug 12, 2022

BUY
$14.13 - $42.55 $9,014 - $27,146
638 Added 3.74%
17,698 $348,000
Q1 2022

May 13, 2022

SELL
$35.3 - $64.68 $42,395 - $77,680
-1,201 Reduced 6.58%
17,060 $722,000
Q4 2021

Feb 11, 2022

SELL
$49.91 - $65.56 $27,250 - $35,795
-546 Reduced 2.9%
18,261 $1.16 Million
Q3 2021

Nov 12, 2021

BUY
$47.8 - $66.66 $124,710 - $173,915
2,609 Added 16.11%
18,807 $1.11 Million
Q2 2021

Aug 13, 2021

BUY
$31.08 - $51.95 $320,776 - $536,175
10,321 Added 175.62%
16,198 $786,000
Q1 2021

May 07, 2021

BUY
$35.64 - $85.46 $570 - $1,367
16 Added 0.27%
5,877 $228,000
Q4 2020

Feb 12, 2021

BUY
$28.07 - $87.83 $164,518 - $514,771
5,861 New
5,861 $363,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $1.65B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.